课题基金 / 基金详情

Characterizing mutations in the a3 V-ATPase subunit in osteoclasts: A key player in bone loss due to inflammatory arthritis

Characterizing mutations in the a3 V-ATPase subunit in osteoclasts: A key player in bone loss due to inflammatory arthritis
破骨细胞中α3 V-ATP酶亚基的突变特征:炎症性关节炎引起的骨质流失的关键因素
批准号:
210556
负责人:
Manolson Morris F
金额:
$44.59万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2010
资助国家:
加拿大
项目状态:
已结题
起止时间:
2010-09-01 至 2015-09-01

项目摘要

项目成果

Manolson Morris F的其他基金

相似基金

相关文献

中文摘要
翻译
理论上的“银弹”疗法是减少破骨细胞性骨吸收,同时增加成骨细胞性骨形成。到目前为止,预防骨质流失的“黄金标准”疗法是双膦酸类药物。
英文摘要
The theoretical "silver-bullet" therapy for pomoting healthier bone is to reduce osteoclastic bone resorption while increasing osteoblastic bone formation. To date, the "gold standard" treatment to prevent bone loss are the bisphosphonates, which do inde
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the role of the V-ATPase "a" subunit in targeting and function: a novel therapeutic target for bone-loss pathologies and cancer
  • 批准号:
    344253
  • 项目类别:
    Operating Grants
  • 资助金额:
    $31.47万
  • 财政年份:
    2016
  • 负责人:
    Manolson Morris F
  • 依托单位:
Characterization of V-ATPase subunit isoforms as therapeutic targets for diverse diseases including bone loss in inflammatory arthritis
  • 批准号:
    254898
  • 项目类别:
    Operating Grants
  • 资助金额:
    $42.21万
  • 财政年份:
    2012
  • 负责人:
    Manolson Morris F
  • 依托单位:
海外基金